|
Vitiligo Support International Inc. (VSI) is a patient driven 501(c)(3) nonprofit organization offering a comprehensive resource of vitiligo education, research and awareness for those whose lives have been affected by vitiligo.
We are here to address your questions and concerns and help you connect with our community. You will find the hope, support and healing that can only be offered by those who understand best - those who have walked in your shoes.
|
|
|
Vitiligo Support - Articles
Featured Articles
| || VSI Articles |
|
New Research Approach Can Potentially Stop Vitiligo in its Tracks
Written by Source: Loyola University Health System
About 1 million Americans suffer a skin disorder called vitiligo, which causes unsightly white patches on the face, hands and other parts of the body. A Loyola University Hospital researcher has won a five-year, $1.7 million federal grant to investigate a new way to treat vitiligo. This research also could point the way to new treatments for melanoma, the deadliest form of skin cancer. More...
|
 |
| || VSI Articles |
|
|
The American Academy of Pediatrics (AAP) Doubles the Amount of Vitamin D it Recommends for Infants, Children and Adolescents
Written by The American Academy of Pediatrics (AAP) News Room
BOSTON - The American Academy of Pediatrics (AAP) is doubling the amount of vitamin D it recommends for infants, children and adolescents. The new clinical report, "Prevention of Rickets and Vitamin D Deficiency in Infants, Children, and Adolescents," recommends all children receive 400 IU a day of vitamin D, beginning in the first few days of life. The previous recommendation, issued in 2003, called for 200 IU per day beginning in the first two months of life. More...
|
|
| || VSI Articles |
|
|
Protopic Immunomodulator (Tacrolimus)
Written by VSI
The following articles/news releases are about a new drug called Protopic Ointment (Tacrolimus). Protopic ointment, an immunomodulator, is currently indicated for the treatment of moderate to severe eczema (atompic dermatitis). Currently, an investigator initiated study is underway with support from Fujisawa Pharmaceuticals of Japan, to evaluate the safety and efficay of Protopic in the treatment of vitiligo. More...
|
|
| || VSI Articles |
|
|
Anti-thyroid peroxidase antibody and vitiligo: a controlled study
Written by BMC Dermatol
Vitiligo is an acquired depigmenting disorder due to destruction of melanocytes. Although many theories have been suggested for its pathogenesis, the role of autoimmunity is the most popular one. The association of vitiligo with autoimmune thyroid diseases and the increased prevalence of autoantibodies including thyroid autoantibodies in vitiligo favor this role. Our objective was to compare the frequency of thyroid peroxidase antibody (anti-TPO) in vitiligo patients with healthy subjects in Iran. More...
|
|
» Recent Articles
|
|
